Abstract
Percutaneous transvascular coronary angioplasty and stenting is one of the most commonly employed interventional procedures for the treatment of occlusive coronary artery disease. The common long-term complication of this treatment is re-stenosis occuring at the site of the atherosclerotic lesion following stenting. The rate of re-stenosis within 6 months could be as high as 20-30% of patients resulting in increased morbidity and tremendous costs to the health care system. The incidence has been somewhat reduced with the development of drug eluting stents, releasing drugs like paclitaxel, sirolimus, zotarolimus and everolimus with varied sustained release profiles. However the long-term benefits from large studies are still controversial and delayed onset of thrombosis is a major ongoing concern and lifelong anti-platelets therapy has been suggested clinically in patients bearing such pharmacological stents. Drug-eluting polymeric bioresorbable stent is being considered to hold immense promise to effectively address such pertinent complications mainly because of its improved biocompatibility, transient nature of supporting the intervened artery, eliminating local effect and damage of permanent metals, allowing smoother restoration of vasoreactivity and physiologic healing, and higher local drug delivery capacity in comparison to permanent metallic stents. In this article we review the current standpoint of drug eluting metallic stent, which has so long been considered as a major medical innovation in the field of pharmaceutical sciences, and its rapid evolution to pharmacological bioresorbable stent in order to promote proper vascular remodeling and achieve better risk-benefit ratio under diverse clinical challenges.
Keywords: Vascular restenosis, thrombosis, drug delivery, bioresorbable stent, vascular remodeling, encapsulation, biopolymers, cardiac therapy, tissue engineering
Current Drug Delivery
Title: Recent Advancements in Pharmacological Stent Therapy Using Polymeric Materials: Opportunities and Challenges
Volume: 7 Issue: 3
Author(s): Arghya Paul, Ezzaldin ElHayek, Dominique Shum-Tim and Satya Prakash
Affiliation:
Keywords: Vascular restenosis, thrombosis, drug delivery, bioresorbable stent, vascular remodeling, encapsulation, biopolymers, cardiac therapy, tissue engineering
Abstract: Percutaneous transvascular coronary angioplasty and stenting is one of the most commonly employed interventional procedures for the treatment of occlusive coronary artery disease. The common long-term complication of this treatment is re-stenosis occuring at the site of the atherosclerotic lesion following stenting. The rate of re-stenosis within 6 months could be as high as 20-30% of patients resulting in increased morbidity and tremendous costs to the health care system. The incidence has been somewhat reduced with the development of drug eluting stents, releasing drugs like paclitaxel, sirolimus, zotarolimus and everolimus with varied sustained release profiles. However the long-term benefits from large studies are still controversial and delayed onset of thrombosis is a major ongoing concern and lifelong anti-platelets therapy has been suggested clinically in patients bearing such pharmacological stents. Drug-eluting polymeric bioresorbable stent is being considered to hold immense promise to effectively address such pertinent complications mainly because of its improved biocompatibility, transient nature of supporting the intervened artery, eliminating local effect and damage of permanent metals, allowing smoother restoration of vasoreactivity and physiologic healing, and higher local drug delivery capacity in comparison to permanent metallic stents. In this article we review the current standpoint of drug eluting metallic stent, which has so long been considered as a major medical innovation in the field of pharmaceutical sciences, and its rapid evolution to pharmacological bioresorbable stent in order to promote proper vascular remodeling and achieve better risk-benefit ratio under diverse clinical challenges.
Export Options
About this article
Cite this article as:
Paul Arghya, ElHayek Ezzaldin, Shum-Tim Dominique and Prakash Satya, Recent Advancements in Pharmacological Stent Therapy Using Polymeric Materials: Opportunities and Challenges, Current Drug Delivery 2010; 7 (3) . https://dx.doi.org/10.2174/156720110791560973
DOI https://dx.doi.org/10.2174/156720110791560973 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Safety Considerations in the Use of Ketorolac for Postoperative Pain
Current Drug Safety Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy ATP-Sensitive K+ Channel Openers: Old Drugs with New Clinical Benefits for the Heart
Current Vascular Pharmacology Common Comorbidities that Alter Heart Failure Prognosis - Shaping New Thinking for Practice
Current Cardiology Reviews RNA Interference in Cancer: Targeting the Anti-Apoptotic Protein c-FLIP for Drug Discovery
Mini-Reviews in Medicinal Chemistry Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure
Current Pharmaceutical Design Molecular Mechanisms of Neuronal Histamine and its Receptors in Obesity
Current Molecular Pharmacology Chemical and Biological Properties of Phenolics in Wine: Analytical Determinations and Health Benefits
Current Organic Chemistry Resident and Non-Resident Stem Cells in Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets <i>Tylophora hirsuta</i> (Wall.) Extracts Ameliorate Diabetes Associated with Inflammation in Alloxan-induced Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets Monogenic Diabetes: Genetics and Relevance on Diabetes Mellitus Personalized Medicine
Current Diabetes Reviews Cardiovascular Involvement in Pediatric Systemic Autoimmune Diseases: The Emerging Role of Noninvasive Cardiovascular Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Modulators of the Vascular Endothelin Receptor in Blood Pressure Regulation and Hypertension
Current Molecular Pharmacology Recurrent Gastrointestinal Bleeding in a Patient with Eisenmenger Syndrome Using Bosentan
Current Drug Safety Non-Transferrin Bound Iron - Determination in Biological Material and Clinical Implications
Current Pharmaceutical Analysis Cyclodextrins as Food Additives and in Food Processing
Current Nutrition & Food Science Chronopharmaceutical Delivery of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Hypertension and Endothelial Dysfunction: Therapeutic Approach
Current Vascular Pharmacology Overexpression of a Modified Amaranth Protein in Escherichia coli with Minimal Media and Lactose as Inducer
Recent Patents on Biotechnology Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry